Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, open label pilot clinical trial with two parallel arms aimed to
compare the efficacy of Raltegravir (RAL) 1200mg QD vs Darunavir/Cobicistat (DRV-cb)
800-150mg QD both in combination with alafenamide/emtricitabine (TAF/FTC) in patients with
Human Inmunodefficiency Virus (HIV) infection and CD4<200 cells/microL
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud